Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: An evidence-based approach

Oncology

Volumn 80, Issue 5-6, 2011, Pages 350-358

  Tassinari, Davide ^a,d   Sartori, Sergio ^b   Papi, Maximilian ^a   Drudi, Fabrizio ^a   Castellani, Cinzia ^a   Carloni, Federica ^a   Tombesi, Paola ^b   Lazzari Agli, Luigi ^c  

^a City Hospital   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c Department of Pneumology   (Italy)

^d NONE   (Italy)

Author keywords

Bevacizumab; Lung cancer; Non squamous non small cell lung cancer; Palliative chemotherapy

Indexed keywords

BEVACIZUMAB;

ADVANCED CANCER; ANEMIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; HYPERTENSION; LUNG NEOPLASMS; NEUTROPENIA; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 79960681851     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328781     Document Type: Article

References (31)

1. Midgley R, Kerr D: Bevacizumab: Current status and future directions. Ann Oncol 2005; 16: 999-1004. (Pubitemid 41418303)
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
3. Hurwith HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
4. Cassidy J, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
5. Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatinbased chemotherapy as first line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
6. Reck M, von-Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27: 1227-1234.
7. Sandler A, Gray R, Perry MC, et al: Paclitaxel- carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Eng J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
8. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Eng J Med 2007; 357: 2666-2676.
9. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet 2007; 370: 2103-2111. (Pubitemid 350296300)
10. Nicolucci A, Grilli R, Alexanian AA, et al: Quality, evaluation and clinical implications of randomized, controlled trials on the treatment of lung cancer: A lost opportunity for meta-analysis. J Am Med Assoc 1989; 262: 2101-2107. (Pubitemid 20001299)
11. Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. (Pubitemid 34746062)
12. Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-1809.
13. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Eng J Med 2002; 346: 92-98. (Pubitemid 34438899)
14. Ramalingam S, Belani CP: State of the art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004; 31(suppl 1):68-74. (Pubitemid 38241023)
15. Gadgeel SM: Histology as a selection factor for treatment. J Thorac Oncol 2009; 4(suppl 1):S79-S81.
16. Hirsch FR, Spreafico A, Novello S, et al: The prognostic and predictive role of histology in advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 1468-1481.
17. Kelly K, Huang C: Biological agents in nonsmall cell lung cancer: A review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol 2008; 3: 664-673. (Pubitemid 351787316)
18. Scagliotti GV, Parikh P, von Pavel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced- stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
19. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009; 361: 947-957.
20. http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/125085s0168lbl. pdf.
21. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product- Information/human/000582/WC500029271.pdf.
22. http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/021462s033lbl. pdf.
23. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product- Information/human/000564/WC500025611.pdf.
24. Manegold C, von Pawel J, Zatloukal P, et al: BO17704 (AVAIL): A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Proceedings ESMO 2008 Congress. Ann Oncol 2008; 19(suppl 8):viii1.
25. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin- versus carboplatin-based chemotherapy in first line treatment of advanced nonsmall- cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857.
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http:// www.ich.org, 2004.
27. Hapani S, Sher A, Chu D, et al: Increased risk of serious hemorrhage with bevacizumab in cancer patients: A meta-analysis. Oncology 2010; 79: 27-38.
28. Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients. A meta-analysis. JAMA 2011; 305: 487-494.
29. Sandler AB, Schiller JH, Gray R, et al: Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009; 27: 1405-1412.
30. Gandara DR: Personalizing therapy of lung cancer; a paradigm shift from empiric to integrated decision-making. J Thorac Oncol 2009; 4(suppl 1):S5-S6.
31. Ramalingam SS: Angiogenesis in lung cancer: Predictive plasma biomarker profiles. J Thorac Oncol 2009; 4(suppl 1):S21-S22.